XTX401
Advanced solid tumors
PreclinicalResearch
Key Facts
About Xilio Therapeutics
Xilio Therapeutics is pioneering a novel approach to cancer treatment by creating therapies that remain inactive in healthy tissue but are selectively activated within tumors. This tumor-selective activation is intended to unlock the full potential of potent immunotherapies, such as cytokines and checkpoint inhibitors, which have historically been limited by severe side effects. The company's lead programs, including XTX101 (anti-CTLA-4) and XTX202 (IL-2), are in clinical development for various solid tumors. Xilio's strategy focuses on building a pipeline of targeted oncology assets to address significant unmet medical needs.
View full company profileTherapeutic Areas
Other Advanced solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1701 | Jiangsu Hengrui Medicine | Phase 1 |
| BAY 1895344 | Bayer | Phase 1 |
| HS-10342 | Hansoh Pharma | Phase 1/2 |
| ANKTIVA® + M-ceNK | ImmunityBio | Phase 1 |
| DFTX-101 | Definium Therapeutics | Phase 1/2 |
| REC-617 | Recursion Pharmaceuticals | Phase 1/2 |
| ZW220 | Zymeworks | Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| IMA402 (TCR Bispecific) | Immatics | Phase 1 |
| IMA403 (TCR Bispecific) | Immatics | Pre-clinical |
| BCA101 | Bicara Therapeutics | Phase 1 |
| AN4005 | Adlai Nortye | Preclinical |